Rechallenge after Clozapine-Induced Neutropenic Events: A Case Series.

Psychopharmacol BullSep 18, 2026
Case ReportPsychiatryOpen access

Sumeet Gupta, Mohamed Ismail, Aysha Zabin et al.

✦ AI-curated · Sources linked

Case in brief

This case series discusses 13 patients who were rechallenged with clozapine after experiencing neutropenic events. The majority, 61.5%, were successfully maintained on the medication without fatalities. The severity of the initial neutropenic episode did not correlate with the success of the rechallenge, suggesting that careful individualised risk-benefit assessments can guide treatment decisions.

Diagnostic / clinical pearl

Clinicians should consider individualised risk-benefit assessments when rechallenging patients with clozapine after neutropenic events, as many can be successfully maintained.

Source

PubMed · PMID 42763640Free full text on PubMed Central

Published in Psychopharmacol Bull. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.